Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Fast Track Designation by the U.S. FDA for first-line treatment of advanced biliary tract cancer
Filed with HKEX · Stock code 9887 · · 4 pages · English
Nanjing Leads Biolabs Co., Ltd. on 6ix
Earlier from Nanjing Leads Biolabs
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
- Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Orphan Drug Designation in Japan
- 2026 Interim report
- Leads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations
Later from Nanjing Leads Biolabs
- Voluntary announcement first patient enrolled in phase ib/II clinical trial of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) in combination therapy for metastatic colorectal cancer
- Voluntary announcement abstracts of six studies published at 2026 ESMO
- Voluntary announcement phase ii study of lbl-024 (opamtistomig, pd-L1/4-1BB bispecific antibody) as first-line treatment for gastric cancer progresses to expansion stage
Follow Nanjing Leads Biolabs into a list and get an email when it puts out news.
Follow Nanjing Leads Biolabs